PARP inhibitor AZD2281
Term · Oncology and biomedicine · MLC-T-ONC-006361
A drug used alone or with other drugs to treat adults with certain types of prostate cancer, pancreatic cancer, breast cancer, or ovarian, fallopian tube, or primary peritoneal cancer. It is also being studied in the treatment of other types of cancer. PARP inhibitor AZD2281 blocks an enzyme involved in many cell functions, including the repair of DNA damage. Blocking this enzyme may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitor AZD2281 is a type of PARP inhibitor. Also called AZD2281, Lynparza, and olaparib.
| Identifier | MLC-T-ONC-006361 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | AZD2281; Lynparza; olaparib |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-006361",
"term": "PARP inhibitor AZD2281",
"field": "Oncology and biomedicine",
"definition": "A drug used alone or with other drugs to treat adults with certain types of prostate cancer, pancreatic cancer, breast cancer, or ovarian, fallopian tube, or primary peritoneal cancer. It is also being studied in the treatment of other types of cancer. PARP inhibitor AZD2281 blocks an enzyme involved in many cell functions, including the repair of DNA damage. Blocking this enzyme may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitor AZD2281 is a type of PARP inhibitor. Also called AZD2281, Lynparza, and olaparib.",
"synonyms": [
"AZD2281",
"Lynparza",
"olaparib"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/parp-inhibitor-azd2281/"
}
Record 12,689 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.